Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. for allegedly failing to disclose a competing acquisition bid during the approval process of its merger with Koito Manufacturing Co., which may have undervalued Cepton shares [1][3][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who traded Cepton shares between July 29, 2024, and January 6, 2025 [1][2]. - The merger proposal from Koito valued Cepton shares at $3.17 each, while a credible third-party bid valued the company at more than double that amount [3][5]. - The Delaware Court of Chancery is currently handling a lawsuit from former shareholders against Cepton's senior officers, revealing that proxy materials for the Koito acquisition concealed material information [4][5]. Group 2: Allegations Against Cepton - Cepton's Board of Directors allegedly did not adequately explore the competing offer and failed to disclose its terms when recommending the Koito transaction to shareholders [5]. - The complaint also suggests that Cepton's CEO had conflicts of interest regarding the Koito proposal, further complicating the situation for shareholders [5].

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against C3.ai, Inc. (NYSE: AI) ("C3.ai" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 26, 2025 through August 8, 2025 (the "Class Period"), Investor Deadline: Investors who purchased or acquired C3.ai securities during the Class Period may, no later than October 21, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. on behalf of investors who acquired shares during the specified Class Period, alleging failure to disclose material concerns regarding a key military contract [1][3]. Group 1: Company Overview - KBR, Inc. is a Houston-based engineering, technology, and government services firm that provides logistics and operations support to various federal agencies, including the Department of Defense [2]. Group 2: Allegations and Impact - The complaint alleges that KBR did not disclose ongoing concerns from the U.S. Department of Defense's Transportation Command (TRANSCOM) about HomeSafe's ability to fulfill the Global Household Goods Contract during the Class Period [3]. - On June 19, 2025, HomeSafe announced the termination of the contract by TRANSCOM, leading to a significant drop in KBR's share price by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period from May 7, 2025, to August 5, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired LifeMD shares during the class period [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) for allegedly concealing significant cost overruns and execution problems on key infrastructure projects, leading to a sharp decline in stock value and investor confidence [1][3][4]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver among its three segments [2]. Allegations and Issues - The lawsuit claims that FLR concealed cost overruns and execution issues on major projects such as the Gordie Howe International Bridge, I-635/LBJ, and I-35, which were impacted by subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategies and failed to disclose the full impact of reduced client spending and macroeconomic uncertainty [3]. Financial Performance - Despite the ongoing issues, FLR reaffirmed its financial guidance in May 2025. However, on August 1, 2025, the company reported second-quarter results that significantly missed expectations, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disappointing results, FLR cut its full-year guidance and experienced a stock price drop of 27.04%, closing at $41.42 on August 1, 2025. Analysts subsequently downgraded the stock due to lost confidence in management's disclosures and project oversight [4].

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation, alleging that the company engaged in a scheme to depress the value of its shares during a go-private transaction, resulting in shareholders receiving an unfair price for their shares [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who sold Sina shares between October 13, 2020, and March 22, 2021, including those who sold during the go-private merger [1][2]. - The complaint claims that important facts were omitted from the proxy materials that shareholders relied on for voting decisions [3]. - It is alleged that the true value of Sina's investment in TuSimple, a U.S.-based autonomous trucking company, was concealed, leading to a cash offer that significantly undervalued shareholders' shares [4]. Group 2: Internal Evidence - Discovery in a related shareholder appraisal proceeding revealed internal documents indicating that senior executives deliberately hid the value of the investment, misleading shareholders [5]. Group 3: Investor Information - Investors who sold SINA securities during the class period have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - For more information regarding the lawsuit, investors can contact Berger Montague [6][8]. Group 4: About the Law Firm - Berger Montague has been a pioneer in securities class action litigation since 1970 and has represented individual and institutional investors for over five decades [7].

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) --  Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class ...

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with HomeSafe, which led to a significant drop in KBR's stock price after the termination of a contract by the U.S. Department of Defense's TRANSCOM [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025 [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The allegations include KBR's failure to disclose concerns from TRANSCOM about HomeSafe's ability to fulfill its obligations under the Global Household Goods Contract [3]. Group 2: Impact on Stock Price - Following the announcement of the contract termination by HomeSafe on June 19, 2025, KBR's shares fell by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 3: Company Background - KBR, Inc. is headquartered in Houston, Texas, and provides engineering, logistics, defense contracting, and mission-critical government services [2].

Core Viewpoint - Berger Montague PC is investigating claims against Altimmune, Inc. following a class action lawsuit related to the company's performance and disclosures regarding its clinical trials [1][3]. Group 1: Company Overview - Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [1]. Group 2: Legal Actions - A class action lawsuit has been filed against Altimmune, with investors who purchased securities between August 10, 2023, and June 25, 2025, having until October 6, 2025, to seek appointment as lead plaintiff [2]. - The lawsuit follows the announcement of topline results from Altimmune's IMPACT Phase 2b trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint [3][4]. Group 3: Financial Impact - Following the announcement of the trial results, Altimmune's stock price dropped from $7.71 on June 25, 2025, to $3.61 on June 26, representing a decline of over 53% in one day [4].

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S by Berger Montague PC on behalf of investors who acquired Novo's publicly traded securities during the specified class period from May 7, 2025, to July 28, 2025 [1][2] Company Summary - Novo Nordisk A/S is a global pharmaceutical company headquartered in Denmark [3] - The lawsuit alleges that Novo understated the impact of the personalization exception to the compounded GLP-1 exclusion, which has allowed continued use of compounded alternatives to its products [3] - The company is accused of overstating the likelihood that patients using less expensive compounded drugs would switch to its branded products, leading to an overestimation of its long-term growth potential [3] Financial Impact - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for fiscal 2025, citing slower-than-expected growth for its products Wegovy® and Ozempic® due to competition from compounded GLP-1 products [4] - Following this announcement, Novo's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, representing a decline of approximately 21.83% in a single day [4]